FibroGen Inc. has announced that Michael Kauffman, M.D., Ph.D., has joined its Board of Directors, effective June 4, 2025. Dr. Kauffman, a veteran in the biotech industry with extensive experience in oncology therapeutic products, is expected to bring significant expertise to support FibroGen's ongoing drug development efforts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-083676), on June 09, 2025, and is solely responsible for the information contained therein.